Osteoblast-induced osteoclast apoptosis by fas ligand/FAS pathway is required for maintenance of bone mass

Cell Death and Differentiation

Volumn 22, Issue 10, 2015, Pages 1654-1664

  Wang, L ^a   Liu, S ^a   Zhao, Y ^a   Liu, D ^b   Liu, Y ^b   Chen, C ^b   Karray, S ^c   Shi, S ^a,b   Jin, Y ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; FASL PROTEIN, MOUSE; NFKB1 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MASS; CELL ACTIVITY; CONTROLLED STUDY; FEMALE; HOMEOSTASIS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; BONE; BONE DENSITY; DISEASE MODEL; METABOLISM; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; BONE AND BONES; BONE DENSITY; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; FEMALE; MICE; NF-KAPPA B P50 SUBUNIT; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84941188471     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.14     Document Type: Article

References (54)

1. Rankin EB, Wu C, Khatri R, Wilson TL, Andersen R, Araldi E et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell 2012; 149: 63-74.
2. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425: 841-846.
3. Greenbaum A, Hsu YM, Day RB, Schuettpelz LG, Christopher MJ, Borgerding JN et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature 2013; 495: 227-230.
4. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425: 836-841.
5. Liu Y, Wang L, Kikuiri T, Akiyama K, Chen C, Xu X et al. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-gamma and TNF-alpha. Nat Med 2011; 17: 1594-1601.
6. Wang L, Zhao Y, Liu Y, Akiyama K, Chen C, Qu C et al. IFN-gamma and TNF-alpha synergistically induce mesenchymal stem cell impairment and tumorigenesis via NFkappaB signaling. Stem Cells 2013; 31: 1383-1395.
7. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 2006; 4: 111-121.
8. Negishi-Koga T, Shinohara M, Komatsu N, Bito H, Kodama T, Friedel RH et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 2011; 17: 1473-1480.
9. Hayashi M, Nakashima T, Taniguchi M, Kodama T, Kumanogoh A, Takayanagi H. Osteoprotection by semaphorin 3 A. Nature 2012; 485: 69-74.
10. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176.
11. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006; 12: 17-25.
12. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 1997; 11: 3482-3496.
13. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3: 889-901.
14. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002; 416: 744-749.
15. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011; 17: 1231-1234.
16. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005; 202: 1261-1269.
17. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-3602.
18. Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble FAS ligand expression on inflammation and tumor cell survival. J Exp Med 2000;191: 1209-1220.
19. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114: 181-190.
20. Zhang Y, Xu G, Zhang L, Roberts AI, Shi Y. Th17 cells undergo FAS-mediated activation-induced cell death independent of IFN-gamma. J Immunol 2008; 181: 190-196.
21. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of FAS ligand in osteoclasts. Cell 2007; 130: 811-823.
22. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996; 2: 1132-1136.
23. Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP et al. Estrogen protects bone by inducing FAS ligand in osteoblasts to regulate osteoclast survival. EMBO J 2008; 27: 535-545.
24. Garcia AJ, Tom C, Guemes M, Polanco G, Mayorga ME, Wend K et al. ERalpha signaling regulates MMP3 expression to induce FASL cleavage and osteoclast apoptosis. J Bone Miner Res 2013; 28: 283-290.
25. Karray S, Kress C, Cuvellier S, Hue-Beauvais C, Damotte D, Babinet C et al. Complete loss of FAS ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele. J Immunol 2004; 172: 2118-2125.
26. Mabrouk I, Buart S, Hasmim M, Michiels C, Connault E, Opolon P et al. Prevention of autoimmunity and control of recall response to exogenous antigen by FAS death receptor ligand expression on T cells. Immunity 2008; 29: 922-933.
27. Rodda SJ, McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 2006; 133: 3231-3244.
28. Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 2012; 10: 544-555.
29. Kovacic N, Grcevic D, Katavic V, Lukic IK, Grubisic V, Mihovilovic K et al. FAS receptor is required for estrogen deficiency-induced bone loss in mice. Lab Invest 2010; 90: 402-413.
30. Jacquin C, Gran DE, Lee SK, Lorenzo JA, Aguila HL. Identification of multiple osteoclast precursor populations in murine bone marrow. J Bone Miner Res 2006; 21: 67-77.
31. Yamaza T, Miura Y, Bi Y, Liu Y, Akiyama K, Sonoyama W et al. Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS One 2008; 3: e2615.
32. Yamaza T, Ren G, Akiyama K, Chen C, Shi Y, Shi S. Mouse mandible contains distinctive mesenchymal stem cells. J Dent Res 2011; 90: 317-324.
33. Kanematsu M, Sato T, Takai H, Watanabe K, Ikeda K, Yamada Y. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res 2000; 15: 1321-1329.
34. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007; 7: 292-304.
35. Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 2009; 15: 757-765.
36. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med 2011; 17: 1235-1241.
37. Wu X, Pang L, Lei W, Lu W, Li J, Li Z et al. Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell 2010; 7: 571-580.
38. Atkins GJ, Kostakis P, Pan B, Farrugia A, Gronthos S, Evdokiou A et al. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res 2003; 18: 1088-1098.
39. Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 2000; 141: 4768-4776.
40. Park H, Jung YK, Park OJ, Lee YJ, Choi JY, Choi Y. Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis. J Immunol 2005; 175: 7193-7201.
41. Nakashima T, Takayanagi H. Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol 2009; 29: 555-567.
42. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 2000; 106: 1229-1237.
43. Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X et al. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 2007; 117: 122-132.
44. Cenci S, Toraldo G, Weitzmann MN, Roggia C, Gao Y, Qian WP et al. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA 2003; 100: 10405-10410.
45. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 2001; 98: 13960-13965.
46. Binder NB, Niederreiter B, Hoffmann O, Stange R, Pap T, Stulnig TM et al. Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. Nat Med 2009; 15: 417-424.
47. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011; 377: 1276-1287.
48. Lewiecki EM. New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol 2011; 7: 631-638.
49. Kikuiri T, Kim I, Yamaza T, Akiyama K, Zhang Q, Li Y et al. Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res 2010; 25: 1668-1679.
50. Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med 2010; 363: 2027-2035.
51. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2: 595-610.
52. Vignery A, Baron R. Dynamic histomorphometry of alveolar bone remodeling in the adult rat. Anat Rec 1980; 196: 191-200.
53. Miura M, Chen XD, Allen MR, Bi Y, Gronthos S, Seo BM et al. A crucial role of caspase-3 in osteogenic differentiation of bone marrow stromal stem cells. J Clin Invest 2004; 114: 1704-1713.
54. Kamijo S, Nakajima A, Ikeda K, Aoki K, Ohya K, Akiba H et al. Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody. Biochem Biophys Res Commun 2006; 347: 124-132.